On November 8, 2017 Molecular Partners AG (MOLN.SW), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin therapies, reported continued progress with its robust pipeline of therapeutic candidates in oncology and ophthalmology, as well as expansion of its early-stage immuno-oncology portfolio (Press release, Molecular Partners, NOV 8, 2017, View Source [SID1234521822]). Today’s R&D update in New York, entitled ”The DARPin Difference – Offering Patients a New Dimension of Protein Therapeutics,” will feature a series of presentations highlighting the scientific rationale and the potential clinical impact of the DARPin approach, as well as Molecular Partners’ continued forward integration and evolution towards becoming a fully integrated biopharmaceutical company.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Today’s event for institutional investors, sell-side analysts, investment bankers, and business development professionals will take place in the Cosmopolitan Suite at the Four Seasons New York, 57 East 57th Street, from 12.00-2.30 pm EST. For those who are unable to attend in person, a live webcast and replay will be accessible.
”A growing body of scientific and clinical evidence suggests that our DARPin drug discovery platform is a powerful and practical engine for developing medicines that make a tangible difference in the lives of patients, physicians and society,” commented Patrick Amstutz, CEO of Molecular Partners. ”With a late-stage asset in ophthalmology, continued progress with two key oncology clinical development programs, and the emergence of MP0310, the first early-stage immuno-oncology compound originating from our I/O DARPin toolbox, we combine the scientific strength of our DARPin platform with a strong financial position.”
In addition to an overview of the Molecular Partners clinical and pre-clinical pipeline, the R&D update event will feature presentations by the following medical and scientific experts:
Prof. Angelo Vacca, MD, Chief of Internal Medicine, University of Bari Medical School, Bari, Italy: Multiple Myeloma (MM)
Kathryn A. Gold, MD, Associate Professor of Medicine, University of California San Diego Moores Cancer Center: Non-Small Cell Lung Cancer (NSCLC)
Richard Baird, PhD, Academic Consultant in Experimental Cancer Therapeutics, University of Cambridge, UK: HER2+ Breast Cancers
Baldo Scassellati Sforzolini, MD, PhD, MBA, Senior Vice President, Clinical Development, Allergan: abicipar, in wet age-related macular degeneration (wet AMD)
Attendees are invited to check in to today’s R&D update at 11:30 am EST. The presentations will begin at 12:15 pm, followed by a Q&A session. Lunch will be served. The live webcast and replay will be accessible here.
Financial Calendar
February 8, 2018 – Publication of Full-year Results 2017 (unaudited)
March 16, 2018 – Expected Publication of 2017 Annual Report
April 18, 2018 – Annual General Meeting
View Source